Page last updated: 2024-10-16

adenine and Hepatitis C

adenine has been researched along with Hepatitis C in 44 studies

Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.

Research Excerpts

ExcerptRelevanceReference
"Fatal lactic acidosis has been reported while on the treatment with Nucleoside/nucleotide analogues (NA) for the treatment of hepatitis B, C and HIV."5.48Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. ( Alsunaid, SR; Ashraf, H; Soubani, AO, 2018)
"Liver steatosis was retrospectively evaluated in all consecutive biopsies performed in the period 2000-2008 in HCV mono-infected and HIV-HCV co-infected patients."5.39Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir. ( Bisi, L; Borghi, V; Cossarizza, A; Manzini, L; Mussini, C, 2013)
"Treatment with lamivudine is initially efficient in both infections but the incidence of lamivudine-resistant HBV emergence increases over time."5.33Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. ( Avilés, JF; Bárcena, R; Barrios, C; Buti, M; Casanovas, T; Cuervas, V; De la Mata, M; Del Campo, S; Delgado, M; Dieguez, ML; Fraga, E; Gonzalez, A; Herrero, JI; Loinaz, C; Mas, A; Moraleda, G; Moreno, JM; Muñoz, R; Otero, A; Prieto, M; Rueda, M; Sousa, JM, 2005)
" Combination therapy with Interferon-α and ribavirin remains the backbone treatment for chronic hepatitis C; the addition of serine protease inhibitors improves the treatment outcome of patients infected with hepatitis C virus genotype 1."4.87Antiviral drugs for viruses other than human immunodeficiency virus. ( Razonable, RR, 2011)
" Chronic hepatitis C can be treated preferably with a combination therapy (pegylated interferons + Ribavirin)."4.82[Hepatitis: associated diseases. Risk groups -- prevention -- treatment]. ( Maier, KP, 2003)
" We also found that co-infection with HCV and treatment by the antiretrovirat drug Tenofovir are significantly associated with the decline in renal function among our patients [p=0."3.79[Crucial risk factors for renal function deterioration of HIV-infected patients at the AIDS Clinic in Rambam Hospital]. ( Hassoun, G; Kedem, E; Mugrabi, F; Pollack, S; Shahar, E, 2013)
" In multivariate analysis, renal dysfunction was associated with older age, non-Hispanic white race/ethnicity, higher body mass index (BMI), hypertension, higher cystatin C levels, and current prescription of ritonavir."3.78Cystatin C and baseline renal function among HIV-infected persons in the SUN Study. ( Brooks, JT; Bush, T; Conley, L; Hammer, J; Henry, K; Kojic, EM; Mondy, K; Overton, ET; Patel, P; Rhame, F, 2012)
" Treatment naive chronic hepatitis C patients should initially receive pegylated interferon and ribavirin dual combination therapy."3.78[Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis]. ( Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I; Ujhelyi, E, 2012)
"We reported previously that octadecyloxyethyl 9-(S)-[3-hydroxy-2-(phosphonomethoxy)-propyl]adenine (ODE-(S)-HPMPA) was active against genotype 1b and 2a hepatitis C virus (HCV) replicons."3.77Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication. ( Beadle, JR; Hostetler, KY; Hwu, JB; Prichard, MN; Schooley, RT; Valiaeva, N; Wyles, DL, 2011)
"The pharmacokinetic data support coadministration of daclatasvir with atazanavir/ritonavir, efavirenz and/or tenofovir."2.78Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. ( Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M, 2013)
" Pharmacokinetic sampling was performed on days 1 through 4 and 22 through 25."2.72Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects. ( Cheng, A; Ebrahimi, R; Kearney, BP; Mittan, A; Ramanathan, S, 2006)
"Five lamivudine patients were switched to tenofovir and in another one adefovir dipivoxil were added."2.46Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature. ( Christodoulou, DK; Katsanos, KH; Tsianos, EV; Tsianos, VE; Vagias, I; Zervou, E; Zioga, H; Zois, CD, 2010)
"Hepatitis A is an acute disease, while patients infected by hepatitis B and hepatitis C viruses are likely to develop chronical infections and severe complications (cancer, cirrhosis)."2.44[The ABC of viral hepatitis]. ( Van Bambeke, F, 2008)
"Fatal lactic acidosis has been reported while on the treatment with Nucleoside/nucleotide analogues (NA) for the treatment of hepatitis B, C and HIV."1.48Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. ( Alsunaid, SR; Ashraf, H; Soubani, AO, 2018)
"Liver steatosis was retrospectively evaluated in all consecutive biopsies performed in the period 2000-2008 in HCV mono-infected and HIV-HCV co-infected patients."1.39Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir. ( Bisi, L; Borghi, V; Cossarizza, A; Manzini, L; Mussini, C, 2013)
"Data on liver fibrosis evolution in HIV-HBV-coinfected patients treated with tenofovir disoproxil fumarate (TDF) are scarce."1.36Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. ( Bonnard, P; Boyd, A; Girard, PM; Lacombe, K; Lascoux-Combe, C; Lasnier, E; Meynard, JL; Miailhes, P; Molina, JM; Wendum, D, 2010)
"Treatment with lamivudine is initially efficient in both infections but the incidence of lamivudine-resistant HBV emergence increases over time."1.33Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. ( Avilés, JF; Bárcena, R; Barrios, C; Buti, M; Casanovas, T; Cuervas, V; De la Mata, M; Del Campo, S; Delgado, M; Dieguez, ML; Fraga, E; Gonzalez, A; Herrero, JI; Loinaz, C; Mas, A; Moraleda, G; Moreno, JM; Muñoz, R; Otero, A; Prieto, M; Rueda, M; Sousa, JM, 2005)
"03 mg/kg, which was approximately 100-fold more potent than that of Imiquimod, and showed an excellent oral bioavailability (F=40%) which was 10-fold improved over 5, a lead compound (F=4%)."1.32Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities. ( Hirota, K; Ichii, S; Isobe, Y; Kawakami, H; Kurimoto, A; Ogino, T; Ogita, H; Sajiki, H; Takaku, H; Tobe, M, 2004)

Research

Studies (44)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (4.55)18.2507
2000's16 (36.36)29.6817
2010's23 (52.27)24.3611
2020's3 (6.82)2.80

Authors

AuthorsStudies
Yang, T1
Oliyai, R1
Kent, KM1
Huhn, GD1
Ramgopal, M1
Jain, MK1
Hinestrosa, F1
Asmuth, DM1
Slim, J1
Goldstein, D1
Applin, S1
Ryu, JH1
Jiang, S1
Cox, S1
Das, M1
Nguyen-Cleary, T1
Piontkowsky, D1
Guyer, B1
Rossaro, L1
Haubrich, RH1
Kim, GW1
Imam, H1
Khan, M1
Siddiqui, A1
MacBrayne, CE1
Marks, KM1
Fierer, DS1
Naggie, S1
Chung, RT1
Hughes, MD1
Kim, AY1
Peters, MG1
Brainard, DM1
Seifert, SM1
Castillo-Mancilla, JR1
Bushman, LR1
Anderson, PL1
Kiser, JJ1
Alsunaid, SR1
Ashraf, H1
Soubani, AO1
Núñez, M1
Mendes-Correa, MC1
Shahar, E1
Mugrabi, F1
Kedem, E1
Hassoun, G1
Pollack, S1
Gulland, A1
Bifano, M1
Hwang, C1
Oosterhuis, B1
Hartstra, J1
Grasela, D1
Tiessen, R1
Velinova-Donga, M1
Kandoussi, H1
Sevinsky, H1
Bertz, R1
Gervasoni, C1
Milazzo, L1
Pezzani, D1
Fucile, S1
Cattaneo, D1
Sagnelli, E1
Pisaturo, M1
Martini, S1
Sagnelli, C1
Filippini, P1
Coppola, N1
Sabo, JP1
Kort, J1
Ballow, C1
Haschke, M1
Battegay, M1
Fuhr, R1
Girlich, B1
Schobelock, M1
Feifel, U1
Lang, B1
Li, Y1
Elgadi, M1
Thong, VD1
Wasitthankasem, R1
Tangkijvanich, P1
Vongpunsawad, S1
Poovorawan, Y1
Renou, C1
Cadranel, JF1
Pariente, A1
Pénaranda, G1
Bourlière, M1
Halfon, P1
Igual, JP1
Harafa, A1
Muller, P1
Bertrand, JJ1
Laugier, R1
Laurent, C1
Bourgeois, A1
Mpoudi-Ngolé, E1
Kouanfack, C1
Ciaffi, L1
Nkoué, N1
Mougnutou, R1
Calmy, A1
Koulla-Shiro, S1
Ducos, J1
Delaporte, E1
Benson, N1
de Jongh, J1
Duckworth, JD1
Jones, HM1
Pertinez, HE1
Rawal, JK1
van Steeg, TJ1
Van der Graaf, PH1
Boyd, A1
Lasnier, E1
Molina, JM1
Lascoux-Combe, C1
Bonnard, P1
Miailhes, P1
Wendum, D1
Meynard, JL1
Girard, PM1
Lacombe, K1
Katsanos, KH1
Tsianos, VE1
Zois, CD1
Zioga, H1
Vagias, I1
Zervou, E1
Christodoulou, DK1
Tsianos, EV1
Mallet, V1
Vallet-Pichard, A1
Pol, S1
Overton, ET1
Patel, P1
Mondy, K1
Bush, T1
Conley, L1
Rhame, F1
Kojic, EM1
Hammer, J1
Henry, K1
Brooks, JT1
Valiaeva, N1
Wyles, DL1
Schooley, RT1
Hwu, JB1
Beadle, JR1
Prichard, MN1
Hostetler, KY1
Razonable, RR1
Makara, M1
Horváth, G1
Gervain, J1
Pár, A1
Szalay, F1
Telegdy, L1
Tornai, I1
Ujhelyi, E1
Hunyady, B1
Kalayjian, RC1
Lau, B1
Mechekano, RN1
Crane, HM1
Rodriguez, B1
Salata, RA1
Krishnasami, Z1
Willig, JH1
Martin, JN1
Moore, RD1
Eron, JJ1
Kitahata, MM1
Borghi, V1
Bisi, L1
Manzini, L1
Cossarizza, A1
Mussini, C1
Coffin, CS1
Fung, SK1
Ma, MM1
Ingiliz, P1
Patrick, I1
Krznaric, I1
Ivanka, K1
Obermeier, M1
Martin, O1
Prescott, LM1
Hirota, K2
Kazaoka, K1
Sajiki, H2
Maier, KP1
Hochman, JA1
Balistreri, WF1
Kurimoto, A1
Ogino, T1
Ichii, S1
Isobe, Y1
Tobe, M1
Ogita, H1
Takaku, H1
Kawakami, H1
Mauss, S1
Sterling, RK1
Sulkowski, MS1
Bárcena, R1
Del Campo, S1
Moraleda, G1
Casanovas, T1
Prieto, M1
Buti, M1
Moreno, JM1
Cuervas, V1
Fraga, E1
De la Mata, M1
Otero, A1
Delgado, M1
Loinaz, C1
Barrios, C1
Dieguez, ML1
Mas, A1
Sousa, JM1
Herrero, JI1
Muñoz, R1
Avilés, JF1
Gonzalez, A1
Rueda, M1
Lee, J1
Wu, CC1
Lee, KJ1
Chuang, TH1
Katakura, K1
Liu, YT1
Chan, M1
Tawatao, R1
Chung, M1
Shen, C1
Cottam, HB1
Lai, MM1
Raz, E1
Carson, DA1
Ramanathan, S1
Cheng, A1
Mittan, A1
Ebrahimi, R1
Kearney, BP1
Iino, S1
Yotsuyanagi, H2
Koike, K2
Van Bambeke, F1
Nakajima, N1
Hanaki, K1
Shimizu, YK1
Ohnishi, S1
Gunji, T1
Nakajima, A1
Nozaki, C1
Mizuno, K1
Odawara, T1
Yoshikura, H1
Pontisso, P1
Belluco, C1
Bertorelle, R1
De Moliner, L1
Chieco-Bianchi, L1
Nitti, D1
Lise, M1
Alberti, A1
Sponseller, CA1
Ramrakhiani, S1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamid[NCT02707601]Phase 3150 participants (Actual)Interventional2016-04-01Completed
Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study)[NCT00146419]699 participants (Actual)Observational2004-03-31Completed
An Open-Label, Randomized Study to Determine the Impact of Antiretroviral Treatment in HCV/HIV-Coinfected Subjects With High CD4+ Cell Count on the Efficacy of Hepatitis C Treatment With Pegylated Interferon Alfa-2A and Ribavirin[NCT00100581]2 participants (Actual)InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percentage of Participants Experiencing Grades 1 Through 4 Adverse Events After Switch to E/C/F/TAF or F/R/TAF Throughout the Study and During Coadministeration With LDV/SOF Treatment

(NCT02707601)
Timeframe: Up to 32 weeks plus 30 days

Interventionpercentage of participants (Number)
E/C/F/TAF + LDV/SOF (Co-administration: Week 8 to Week 20)62.5
F/R/TAF + LDV/SOF (Co-administration: Week 8 to Week 20)69.4
E/C/F/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV Week 12)83.8
F/R/TAF + LDV/SOF (Whole Study: Day 1 to Post-HCV to Week 12)79.7

Percentage of Participants With HCV RNA < LLOQ at 12 Weeks After Discontinuation of LDV/SOF Treatment (SVR12)

Sustained Virologic Response (SVR12) was defined as HCV RNA < the lower limit of quantitation (LLOQ) at 12 weeks after stopping LDV/SOF treatment. (NCT02707601)
Timeframe: HCV Posttreatment Week 12

Interventionpercentage of participants (Number)
E/C/F/TAF + LDV/SOF98.6
F/R/TAF + LDV/SOF95.8

Percentage of Participants With HCV RNA < LLOQ at 4 Weeks After Discontinuation of LDV/SOF Treatment (SVR4)

SVR4 was defined as HCV RNA < LLOQ at 4 weeks after stopping LDV/SOF treatment. (NCT02707601)
Timeframe: HCV Posttreatment Week 4

Interventionpercentage of participants (Number)
E/C/F/TAF + LDV/SOF98.6
F/R/TAF + LDV/SOF98.6

Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL (Virologic Failure) 24 Weeks After Start of the F/TAF-Based Regimen Using Modified FDA Snapshot Algorithm

The percentage of participants with HIV-1 RNA ≥ 50 copies/mL 24 weeks after start of the F/TAF-based regimen were analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT02707601)
Timeframe: 24 weeks after start of HIV treatment

Interventionpercentage of participants (Number)
E/C/F/TAF + LDV/SOF1.4
F/R/TAF + LDV/SOF1.4

Reviews

13 reviews available for adenine and Hepatitis C

ArticleYear
Viral hepatitis and HIV: update and management.
    Antiviral therapy, 2013, Volume: 18, Issue:3 Pt B

    Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Therapy, Combina

2013
Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:10

    Topics: Adenine; Antiviral Agents; Coinfection; DNA, Viral; Drug Therapy, Combination; Guanine; Hepacivirus;

2014
Inflammatory bowel disease and hepatitis B and C in Western Balkans: a referral centre study and review of the literature.
    Journal of Crohn's & colitis, 2010, Volume: 4, Issue:4

    Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Colitis, Ulcerative; Crohn Disease; Drug Therapy

2010
The impact of human immunodeficiency virus on viral hepatitis.
    Liver international : official journal of the International Association for the Study of the Liver, 2011, Volume: 31 Suppl 1

    Topics: Adenine; Antiviral Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Emtricitab

2011
Antiviral drugs for viruses other than human immunodeficiency virus.
    Mayo Clinic proceedings, 2011, Volume: 86, Issue:10

    Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet;

2011
[Hepatitis: associated diseases. Risk groups -- prevention -- treatment].
    Praxis, 2003, Aug-13, Volume: 92, Issue:33

    Topics: Adenine; Adult; Antiviral Agents; Child; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B S

2003
Chronic viral hepatitis: always be current!
    Pediatrics in review, 2003, Volume: 24, Issue:12

    Topics: Adenine; Adolescent; Adult; Antiviral Agents; Child; Female; Hepacivirus; Hepatitis B; Hepatitis B v

2003
Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection.
    Seminars in liver disease, 2004, Volume: 24 Suppl 2

    Topics: Adenine; Antiviral Agents; Comorbidity; Hepacivirus; Hepatitis B virus; Hepatitis C; Hepatitis C, Ch

2004
[Drugs for hepatitis B and C infection].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Feb-28, Volume: 65 Suppl 2 Pt. 1

    Topics: Adenine; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B; Hepatitis B virus; Hepat

2007
[Mechanisms of drug resistance in hepatitis viruses B and C].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Feb-28, Volume: 65 Suppl 2 Pt. 1

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Guanine; Hepacivirus; Hepatit

2007
Drug resistance in antiviral treatment for infections with hepatitis B and C viruses.
    Journal of gastroenterology, 2007, Volume: 42, Issue:5

    Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepacivirus; Hepatitis B; Hepatitis B vi

2007
[The ABC of viral hepatitis].
    Journal de pharmacie de Belgique, 2008, Volume: 63, Issue:1

    Topics: Adenine; Antiviral Agents; Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis, Viral, Human; Humans; I

2008
Treatment of hepatitis B and C following liver transplantation.
    Current gastroenterology reports, 2002, Volume: 4, Issue:1

    Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Disease Progression; Drug Resistance; Drug Ther

2002

Trials

5 trials available for adenine and Hepatitis C

ArticleYear
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
    PloS one, 2020, Volume: 15, Issue:1

    Topics: Adenine; Adult; Aged; Alanine; Benzimidazoles; Coinfection; Drug Combinations; Drug Resistance, Vira

2020
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
    The Journal of antimicrobial chemotherapy, 2018, 08-01, Volume: 73, Issue:8

    Topics: Adenine; Adult; Antiviral Agents; Benzimidazoles; Coinfection; Drug Interactions; Fluorenes; Hepatit

2018
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
    Antiviral therapy, 2013, Volume: 18, Issue:7

    Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates;

2013
Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014, Nov-15, Volume: 59, Issue:10

    Topics: Adenine; Adult; Alkynes; Aminoisobutyric Acids; Anti-HIV Agents; Antiretroviral Therapy, Highly Acti

2014
Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.
    Journal of clinical pharmacology, 2006, Volume: 46, Issue:5

    Topics: Adenine; Adult; Antiviral Agents; Drug Interactions; Female; Hepatitis C; HIV Infections; Humans; Ma

2006

Other Studies

26 other studies available for adenine and Hepatitis C

ArticleYear
The making of the one pill-Developing single tablet regimens for HIV and for HCV.
    Antiviral therapy, 2022, Volume: 27, Issue:2

    Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Diso

2022
    The Journal of biological chemistry, 2020, 09-11, Volume: 295, Issue:37

    Topics: Adenine; DEAD Box Protein 58; Hep G2 Cells; Hepatitis B; Hepatitis C; Humans; Immune Evasion; Immuni

2020
Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient.
    Transplant infectious disease : an official journal of the Transplantation Society, 2018, Volume: 20, Issue:5

    Topics: Acidosis, Lactic; Adenine; Aged; Alanine; Antiviral Agents; Fatal Outcome; Hematopoietic Stem Cell T

2018
[Crucial risk factors for renal function deterioration of HIV-infected patients at the AIDS Clinic in Rambam Hospital].
    Harefuah, 2013, Volume: 152, Issue:4

    Topics: Adenine; Adult; Aged; Anti-HIV Agents; Coinfection; Female; Glomerular Filtration Rate; Hepatitis C;

2013
WHO survey finds half of countries do not have clinical guidelines for treating hepatitis.
    BMJ (Clinical research ed.), 2013, Jul-24, Volume: 347

    Topics: Adenine; Antiviral Agents; Drugs, Essential; Global Health; Guanine; Health Priorities; Hepatitis B;

2013
Telaprevir therapy, renal impairment, and their effects on the pharmacokinetics of tenofovir in HIV/hepatitis C virus coinfected patients.
    AIDS (London, England), 2014, Jan-14, Volume: 28, Issue:2

    Topics: Adenine; Adult; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Kidney Diseases; Male; Oligop

2014
Prevalence of Thymine--Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Adenine; Adult; Alleles; Antiviral Agents; Asian People; Case-Control Studies; Dinucleotide Repeats;

2015
Adefovir combined with hepatitis C virus treatment may prevent hepatitis B reactivation after hepatitis C virus eradication in hepatitis B and C virus carriers.
    European journal of gastroenterology & hepatology, 2008, Volume: 20, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; Carrier State; Drug Therapy, Combination; Hepatitis B; Hepatitis B

2008
High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy.
    HIV medicine, 2010, Volume: 11, Issue:1

    Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; Anti-Retroviral Agents; Cameroon; Comorbidity; Female;

2010
Pharmacokinetic-pharmacodynamic modeling of alpha interferon response induced by a Toll-like 7 receptor agonist in mice.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:3

    Topics: Adenine; Animals; Animals, Outbred Strains; Antiviral Agents; Cell Line, Tumor; Hepacivirus; Hepatit

2010
Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use.
    Antiviral therapy, 2010, Volume: 15, Issue:7

    Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort

2010
Cystatin C and baseline renal function among HIV-infected persons in the SUN Study.
    AIDS research and human retroviruses, 2012, Volume: 28, Issue:2

    Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; CD4 Lymphocyte Count; Cohort Studies; Cross-Sectio

2012
Synthesis and antiviral evaluation of 9-(S)-[3-alkoxy-2-(phosphonomethoxy)propyl]nucleoside alkoxyalkyl esters: inhibitors of hepatitis C virus and HIV-1 replication.
    Bioorganic & medicinal chemistry, 2011, Aug-01, Volume: 19, Issue:15

    Topics: Adenine; Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Organophosphonat

2011
[Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
    Orvosi hetilap, 2012, Mar-11, Volume: 153, Issue:10

    Topics: Adenine; Antiviral Agents; Comorbidity; Consensus; Drug Administration Schedule; Drug Therapy, Combi

2012
Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.
    AIDS (London, England), 2012, Sep-24, Volume: 26, Issue:15

    Topics: Adenine; Adult; AIDS-Associated Nephropathy; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies;

2012
Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir.
    Infection, 2013, Volume: 41, Issue:2

    Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Dideoxynucleosides; Fatty Liver; Female; Genotype; Hep

2013
Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.
    Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2012, Volume: 26, Issue:12

    Topics: Adenine; Allied Health Personnel; Antibodies, Viral; Antiviral Agents; Canada; Coinfection; Drug Res

2012
Sexually transmitted infection with an immune-escape mutant hepatitis B virus in an hepatitis B virus-vaccinated individual with acute HIV-hepatitis C virus infection.
    AIDS (London, England), 2013, Feb-20, Volume: 27, Issue:4

    Topics: Acute Disease; Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Deoxycytidine; Drug

2013
Highlights of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
    The Body positive, 2002, Volume: 15, Issue:3

    Topics: Adenine; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Administration Schedule; Dr

2002
Synthesis and biological evaluation of 2,8-disubstituted 9-benzyladenines: discovery of 8-mercaptoadenines as potent interferon-inducers.
    Bioorganic & medicinal chemistry, 2003, Jul-03, Volume: 11, Issue:13

    Topics: Adenine; Animals; Antiviral Agents; Cells, Cultured; Drug Design; Gene Expression Regulation; Hepati

2003
Synthesis and evaluation of 2-substituted 8-hydroxyadenines as potent interferon inducers with improved oral bioavailabilities.
    Bioorganic & medicinal chemistry, 2004, Mar-01, Volume: 12, Issue:5

    Topics: Adenine; Administration, Oral; Aminoquinolines; Animals; Biological Availability; Cells, Cultured; D

2004
[Viral hepatitis B/C and HIV. Therapy of double infections].
    MMW Fortschritte der Medizin, 2003, Apr-28, Volume: 145 Spec No 1

    Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as T

2003
Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus.
    Transplantation proceedings, 2005, Volume: 37, Issue:9

    Topics: Adenine; Alanine Transaminase; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B e Antigens;

2005
Activation of anti-hepatitis C virus responses via Toll-like receptor 7.
    Proceedings of the National Academy of Sciences of the United States of America, 2006, Feb-07, Volume: 103, Issue:6

    Topics: Adenine; Animals; Antiviral Agents; Cells, Cultured; Female; Hepacivirus; Hepatitis C; Hepatocytes;

2006
Hybridization-AT-tailing (HybrAT) method for sensitive and strand-specific detection of DNA and RNA.
    Biochemical and biophysical research communications, 1998, Jul-30, Volume: 248, Issue:3

    Topics: Adenine; Base Sequence; DNA; DNA-Directed DNA Polymerase; Hepatitis C; Hepatitis C Antibodies; Human

1998
Hepatitis C virus infection associated with human hepatocellular carcinoma: lack of correlation with p53 abnormalities in Caucasian patients.
    Cancer, 1998, Oct-15, Volume: 83, Issue:8

    Topics: Adenine; Aged; Carcinoma, Hepatocellular; Codon; Cohort Studies; DNA, Viral; Exons; Female; Genes, p

1998
chemdatabank.com